Isotoxic intensity modulated radiotherapy in stage III NSCLC - a feasibility study
Bayman, Neil A
Harden, S. V.
Ryder, W. D.
AffiliationThe Christie NHS Foundation Trust, Wilmslow Road, Manchester, UK
MetadataShow full item record
AbstractPurpose: Not all patients with stage III NSCLC are suitable for concurrent chemoradiotherapy (cCRT). Local failure rate is high for sequential CRT and as such, there is a rationale for treatment intensification. Methods and materials: Isotoxic intensity modulated radiotherapy (IMRT) is a multicentre feasibility study that combines different intensification strategies including hyperfractionation, acceleration and dose escalation facilitated by IMRT. Patients with unresectable stage III NSCLC, ECOG PS 0-2 and unsuitable for cCRT were recruited. A minimum of 2 cycles of platinum-based chemotherapy was compulsory before starting radiotherapy (RT). Radiation dose was increased until a maximum dose of 79.2Gy was reached or ≥ 1 of the organs at risk met pre-defined constraints. RT was delivered in 1.8Gy fractions twice-daily and an RT quality assurance programme was implemented. The primary objective was the delivery of isotoxic IMRT to a dose of > 60Gy equivalent dose in 2Gy fractions (EQD2 assuming an α/β ratio of 10 Gy for acute reacting tissues). Results: 37 patients were recruited from 7 UK centres. Median age = 69.9 years (range 46-86). Male:Female ratio = 17:18. ECOG PS=0, 5 (14.2%), PS=1, 27 (77.1%), PS=2, 3 (8.6%). Stage IIIA:IIIB ratio 22 (62.9%):13 (37.1%). Of 37 patients, 2 (5.4%) failed to achieve EQD2 >60Gy. Median prescribed tumor dose was 77.4Gy (61.2 - 79.2Gy). Maximum dose of 79.2Gy was achieved in 14 (37.8%) patients. Grade 3 esophagitis was reported in 2 patients and no patients developed grade 3-4 pneumonitis. There were 3 grade 5 events: acute radiation pneumonitis, bronchopulmonary haemorrhage and acute lung infection. Median follow-up at time of analysis was 25.4 (8.0 - 44.2) months for 11 out of 35 survivors. The median survival was 18.1 months with 95% CI (13.9, 30.6), 2-year overall survival was 33.6%; 95% CI (17.9, 50.1) and progression-free survival was 23.9%; 95% CI (11.3, 39.1). Conclusions: Isotoxic IMRT is a well-tolerated and feasible approach to treatment intensification.
CitationHaslett K, Bayman N, Franks K, Groom N, Harden SV, Harris C, et al. Isotoxic Intensity Modulated Radiation Therapy in Stage III Non-Small Cell Lung Cancer: A Feasibility Study. Int J Radiat Oncol Biol Phys. 2020.
JournalInternational Journal of Radiation Oncology Biology Physics
- Simultaneous Integrated Boost for Radiation Dose Escalation to the Gross Tumor Volume With Intensity Modulated (Photon) Radiation Therapy or Intensity Modulated Proton Therapy and Concurrent Chemotherapy for Stage II to III Non-Small Cell Lung Cancer: A Phase 1 Study.
- Authors: Jeter MD, Gomez D, Nguyen QN, Komaki R, Zhang X, Zhu X, O'Reilly M, Fossella FV, Xu T, Wei X, Wang H, Yang W, Tsao A, Mohan R, Liao Z
- Issue date: 2018 Mar 1
- Protocol for the isotoxic intensity modulated radiotherapy (IMRT) in stage III non-small cell lung cancer (NSCLC): a feasibility study.
- Authors: Haslett K, Franks K, Hanna GG, Harden S, Hatton M, Harrow S, McDonald F, Ashcroft L, Falk S, Groom N, Harris C, McCloskey P, Whitehurst P, Bayman N, Faivre-Finn C
- Issue date: 2016 Apr 15
- Long-term clinical outcome of intensity-modulated radiotherapy for inoperable non-small cell lung cancer: the MD Anderson experience.
- Authors: Jiang ZQ, Yang K, Komaki R, Wei X, Tucker SL, Zhuang Y, Martel MK, Vedam S, Balter P, Zhu G, Gomez D, Lu C, Mohan R, Cox JD, Liao Z
- Issue date: 2012 May 1
- Image guided hypofractionated 3-dimensional radiation therapy in patients with inoperable advanced stage non-small cell lung cancer.
- Authors: Osti MF, Agolli L, Valeriani M, Falco T, Bracci S, De Sanctis V, Enrici RM
- Issue date: 2013 Mar 1
- Impact of Intensity-Modulated Radiation Therapy Technique for Locally Advanced Non-Small-Cell Lung Cancer: A Secondary Analysis of the NRG Oncology RTOG 0617 Randomized Clinical Trial.
- Authors: Chun SG, Hu C, Choy H, Komaki RU, Timmerman RD, Schild SE, Bogart JA, Dobelbower MC, Bosch W, Galvin JM, Kavadi VS, Narayan S, Iyengar P, Robinson CG, Wynn RB, Raben A, Augspurger ME, MacRae RM, Paulus R, Bradley JD
- Issue date: 2017 Jan